The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic ...

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The Food and Drug Administration approved cabozantinib, or Cabometyx, marketed by Exelixis (EXEL), for adult and pediatric patients 12 years of ...

While remote and hybrid job postings have reduced slightly, the IT sector leads with the largest number of such postings, ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Welcome to the latest edition of the Pnet Job Market Trends Report, where you can gain data-driven insights into South African online labour market trends. The monthly report reviews local hiring ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Small-to-Medium Enterprises (SMEs) are the backbone of South Africa’s economy. They create jobs, foster innovation, and drive economic growth in every sector – from manufacturing to tech, retail, and ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.